Search research articles
Contact Us
Filters
Showing results (1-10 of 165) with videos related to
Page
of 17
Sort By:
Frontiers in Oncology
|
July 30, 2016
Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents
Natalie J Serkova, S Gail Eckhardt
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2007
Sunitinib: from rational design to clinical efficacy
Laura Q M Chow, S Gail Eckhardt
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2008
Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL)
Avi Ashkenazi, Pamela Holland, S Gail Eckhardt
Nature Reviews. Clinical Oncology
|
November 11, 2015
The changing landscape of phase I trials in oncology
Kit Man Wong, Anna Capasso, S Gail Eckhardt
Expert Opinion on Investigational Drugs
|
April 13, 2012
JAK2 inhibition for the treatment of hematologic and solid malignancies
Brian L Harry, S Gail Eckhardt, Antonio Jimeno
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 17, 2009
Clinical applications of metabolomics in oncology: a review
Jennifer L Spratlin, Natalie J Serkova, S Gail Eckhardt
The Lancet. Oncology
|
September 2, 2008
Targeted manipulation of apoptosis in cancer treatment
Justin A Call, S Gail Eckhardt, D Ross Camidge
Current Opinion in Molecular Therapeutics
|
November 29, 2007
NMR-based metabolomics: translational application and treatment of cancer
Natalie J Serkova, Jennifer L Spratlin, S Gail Eckhardt
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2007
A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man
Erica L Bradshaw-Pierce, S Gail Eckhardt, Daniel L Gustafson
Clinical Advances in Hematology & Oncology : H&O
|
December 5, 2006
Novel targets in solid tumors: MEK inhibitors
Wells A Messersmith, Manuel Hidalgo, Michael Carducci, et al.
Page
of 17
Search research articles
Search
Showing results (1-10 of 165) with videos related to
Sort By:
Page
of 17
Frontiers in Oncology
|
July 30, 2016
Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents
Natalie J Serkova, S Gail Eckhardt
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2007
Sunitinib: from rational design to clinical efficacy
Laura Q M Chow, S Gail Eckhardt
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2008
Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL)
Avi Ashkenazi, Pamela Holland, S Gail Eckhardt
Nature Reviews. Clinical Oncology
|
November 11, 2015
The changing landscape of phase I trials in oncology
Kit Man Wong, Anna Capasso, S Gail Eckhardt
Expert Opinion on Investigational Drugs
|
April 13, 2012
JAK2 inhibition for the treatment of hematologic and solid malignancies
Brian L Harry, S Gail Eckhardt, Antonio Jimeno
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 17, 2009
Clinical applications of metabolomics in oncology: a review
Jennifer L Spratlin, Natalie J Serkova, S Gail Eckhardt
The Lancet. Oncology
|
September 2, 2008
Targeted manipulation of apoptosis in cancer treatment
Justin A Call, S Gail Eckhardt, D Ross Camidge
Current Opinion in Molecular Therapeutics
|
November 29, 2007
NMR-based metabolomics: translational application and treatment of cancer
Natalie J Serkova, Jennifer L Spratlin, S Gail Eckhardt
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2007
A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man
Erica L Bradshaw-Pierce, S Gail Eckhardt, Daniel L Gustafson
Clinical Advances in Hematology & Oncology : H&O
|
December 5, 2006
Novel targets in solid tumors: MEK inhibitors
Wells A Messersmith, Manuel Hidalgo, Michael Carducci, et al.
Page
of 17